Circadian Rhythm Sleep Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Circadian Rhythm Sleep Treatment Market By Treatment Type (Light Therapy, Drug Therapy, Chronotherapy), By Disorder (Delayed Sleep Phase Syndrome, Advanced Sleep Phase Syndrome, Irregular Sleep-Wake Disorder, Non-24-h Sleep-Wake Syndrome, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2022-2029

[150 Pages Report] Circadian Rhythm Sleep Treatment Market size was valued around US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.5% during the forecast period (2022-2029).

Circadian Rhythm Sleep Treatment Market - Strategic Insights

To Get a Free Sample Click here

Circadian rhythm sleep disorders (CRSD) are sleep disorders that affect the timing of sleep. CRSDs arise from a persistent pattern of sleep/wake disturbances caused either by dysfunction in one's biological clock system or by a misalignment between one's endogenous oscillator and externally imposed cues. The primary event in circadian rhythm sleep treatment is depression of melatonin levels and irregular melatonin levels during the circadian body clock. Treatment options include bright light therapy, medications, behavioral therapy and drugs.  

Market Dynamics

Increasing awareness about sleep disorders and technological advancements are expected to drive the circadian rhythm sleep treatment market.

The increasing prevalence of sleep disorders is expected to drive market growth.

According to the World Sleep Society report 2021. 35% of people believe they do not get enough sleep, which impacts their physical and mental health. Approximately 4% of adults suffer from obstructive sleep apnea (OSA). 21 If not treated properly, OSA can have a negative impact on a person's health and well-being. Restless Legs Syndrome is a common disorder that affects 3-10% of the population, though the number of people affected and the severity of the condition vary by country. Furthermore, each breathing pause can last from 10 seconds to more than a minute and is accompanied by a drop in oxygen. Each hour, the events may occur 5 to 50 times or more. This strains the heart and can lead to various serious health problems.

Besides that, insomnia affects 30-45% of the adult population. Primary insomnia (insomnia caused by no underlying condition) affects 1-10% of the general population, with the elderly accounting for up to 25%. Inadequate or poor-quality sleep also makes us more prone to accidents. Insomniacs are seven times more likely than good sleepers to be involved in an accident that results in death or serious injury. According to studies, people who have insomnia exhibit more symptoms of anxiety and depression than those who do not. Therefore, there is an increase in the demand for the treatment of sleep disorders. Thus, from the above-mentioned factors, the market is expected to drive in the forecast period.

Side effects associated with the drugs to treat circadian rhythm sleep are expected to hamper the market growth.

Melatonin supplements are laboratory-created versions of the sleep hormone that a doctor may prescribe for delayed sleep-wake phase disorder, irregular sleep-wake rhythm disorder, and non-24-hour sleep-wake rhythm disorder. Aside from its benefits, the drug is associated with side effects such as dizziness and fatigue. Thus, from the above-mentioned factors, the market is expected to hamper the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted the circadian rhythm sleep treatment market. Several studies showed the severe impact of COVID-19 on quality of sleep, chronic fatigue, anxiety, and depressive symptoms in caregivers, healthcare staff, patients affected by chronic diseases, and healthy subjects due to prolonged lockdown. Furthermore, the recent outbreak of the COVID-19 pandemic, with tens of thousands of infected patients, has most likely directly affected sleep and circadian rhythms in patients with SARS-CoV-2. Chronotherapy is a new concept that is becoming more popular in sleep medicine. Medication is administered to patients in accordance with their circadian rhythms. Chronotherapy can reduce drug side effects while optimizing therapeutic impact. Furthermore, it can achieve the same efficacy at a lower dose. Patients with COVID-19 may benefit greatly from chronotherapy. For instance, a recent study found that statins significantly reduce COVID-19 severity by lowering cholesterol, which the SARS-CoV-2 uses to infect lung epithelial cells, making hyperlipidemia a risk factor for mortality in COVID-19 patients. There is strong evidence that cholesterol synthesis peaks between 12 and 6 a.m. and that giving the same statin dose in the evening or nighttime significantly reduced cholesterol levels in patients compared to the same dose in the morning. Therefore, there is an increase in the demand for circadian rhythm sleep treatment.

In contrast, decrease in demand for sleeping aids devices and drugs for sleep disorders. Furthermore, market players have decreased investment in raw materials and resources owing to the closure of manufacturing facilities to protect workers in all regions. Thus, from the above-mentioned factors, the market got affected. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Bright light therapy segment is expected to hold the largest market share in circadian rhythm sleep treatment

The bright light therapy segment accounted for the largest market share in 2021. The segment benefits because bright light therapy is used to manage circadian rhythm disorders such as delayed sleep phase syndrome (DSPS), a condition that shifts the normal sleeping pattern outside the standard norm. People with DSPS typically do not fall asleep until several hours after midnight. They have difficulty waking up in the morning, making it difficult to maintain a normal work or school schedule. However, if they are allowed to follow their schedules, their sleep quality is otherwise normal. Bright light therapy is used to restore normal sleeping patterns gradually. The light exposure timing is critical for treatment.

Moreover, exposure to bright light in the evening may help the patient with an advanced sleep disorder. Therefore, there is an increase in the adoption of bright light therapy. Thus, from the above-mentioned factors, the market segment accounted for the largest market share in the forecast period.

 Geographical Analysis

North America region holds the largest market share in the global circadian rhythm sleep treatment

North America region accounted for the largest market share in 2021. The increasing prevalence of sleeping disorders, increasing awareness about sleep disorders, product launches and collaborations by the market players, and increasing government investments in research to improve sleep are the factors to drive the market in the forecast period. For instance, on March 19, 2021, the World Sleep Society conducted a World Sleep Day annual event to raise awareness of sleep disorders and their burden on society. Moreover, 71,000 individuals are injured annually in the United States due to sleep-related accidents. Sleep-related accidents kill 1,550 people. In addition, 46% of people with frequent sleep disturbances report missing work or events or making mistakes at work, compared to 15% of healthy sleepers. Furthermore, a study conducted in the United States estimated the annual costs of insomnia to be between $92.5 billion and $107.5 billion. Thus, from the above-mentioned factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the circadian rhythm sleep treatment market are Beurer GmbH, Fitbit, Inc., Koninklijke Philips, Compass Health Brands (Carex Health), Natus Medical, Compumedics, Lucimed (Luminette), Samarit Medical AG, ResMed Inc., BMC Medical Co., Ltd and SOMNOmedics GmbH.

On May 4, 2022, Jazz Pharmaceuticals plc and Sumitomo Pharma Co., Ltd. announced an exclusive licensing agreement in which Jazz has acquired development and commercialization rights for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia, and other sleep disorders. This molecule is known as JZP441.

Teva Pharmaceutical Industries Limited:

Overview:

Teva Pharmaceutical Industries Limited is an American-Israeli pharmaceutical company that develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates in two separate segments, Generic Medicines and Specialty Medicines. It focuses on the central nervous system, pain, respiratory, and oncology areas. Teva API's portfolio comprises over 400 quality APIs manufactured at 16 state-of-the-art production facilities, employing over 5,000 highly-trained professionals. Teva API greatly emphasizes streamlining API development production and product lifecycle management (PLM) processes. The company scientists are known for their expertise in chemical synthesis, fermentation, high potency, plant extract, synthetic peptides, vitamin D derivatives, prostaglandins, analytical science, powder technology and solid-3 state characterization.

­Product Portfolio:

Melatonin Teva XL 2mg PR Tablets: Melatonin Teva XL is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

The global circadian rhythm sleep treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Cardiac Rhythm Management Devices Market

Cardiac Arrhythmia Monitoring Devices Market

Cellulite Treatment Market

FAQ

What is the Circadian Rhythm Sleep Treatment Market growth?

The market is growing at a CAGR of 4.9%

What is Circadian Rhythm Sleep Treatment Market size in 2021

The Circadian Rhythm Sleep Treatment Market size was valued at USD YY million in 2021

Who are the key players in Circadian Rhythm Sleep Treatment Market?

Vanda Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Mylan N.V, Fitbit, Koninklijke Philips